Molecular tumor profiling has become an important diagnostic for prostate cancer, allowing for personalized treatment regimens based on somatic and germline genetic information. We report a 67-year-old patient with metastatic castrate-resistant prostate cancer which was intermittently responsive to androgen-deprivation therapy, docetaxel, abiraterone, radium-223, Sipuleucel-T, and radiotherapy who ultimately demonstrated a remarkable and durable response to pembrolizumab. Our case report underlines the significance of early tumor molecular profiling in aggressive or atypical prostate cancer patients and exhibits the potential for a remarkable clinical response with immunotherapy in candidates with the appropriate tumor profiles.
Keyphrases
- prostate cancer
- radical prostatectomy
- case report
- squamous cell carcinoma
- small cell lung cancer
- advanced non small cell lung cancer
- early stage
- single cell
- stem cells
- locally advanced
- oxidative stress
- mesenchymal stem cells
- dna methylation
- genome wide
- dna repair
- dna damage
- replacement therapy
- bone marrow
- health information
- cancer therapy
- human health